Biomea Fusion

BMEA

Market cap $115M

Overview Fund Activity

1.93 USD

-0.05

2.53%

At close Updated Sep 12, 4:00 PM EDT

Pre-market

After hours

1.93

0.00

0%

1 day

-2.53%

5 days

0.52%

1 month

16.97%

3 months

-26.05%

6 months

-21.54%

Year to date

-47.7%

1 year

-74.27%

5 years

-89.62%

10 years

-89.62%

About: Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.

Employees: 63

Healthcare Biotechnology

0

Funds holding %

of 7,462 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

143% more call options, than puts

Call options by funds: $2.77M | Put options by funds: $1.14M

17.57% more ownership

Funds ownership: 58.87% [Q1] → 76.44% (+17.57%) [Q2]

10% more capital invested

Capital invested by funds: $47M [Q1] → $51.7M (+$4.7M) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

4% less repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 23

10% less funds holding

Funds holding: 94 [Q1] → 85 (-9) [Q2]

24% less first-time investments, than exits

New positions opened: 28 | Existing positions closed: 37

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$5

159% upside

Avg. target

$9.5

392% upside

High target

$16

729% upside

4 analyst ratings

4 positive

100%

0 neutral

0%

0 negative

0%

Jefferies Roger Song	$5	Buy Initiated	28 Aug 2025
Citigroup Yigal Nochomovitz	$7	Buy Maintained	11 Aug 2025
Scotiabank George Farmer	$10	Sector Outperform Maintained	6 Aug 2025
D. Boral Capital Jason Kolbert	$16	Buy Maintained	6 Aug 2025

See Analyst Rankings

Financial journalist opinion

The Motley Fool

Biomea Fusion (BMEA) Q2 Loss Drops 44%

Biomea Fusion (BMEA) Q2 Loss Drops 44%

Biomea Fusion (BMEA) Q2 Loss Drops 44%

Biomea Fusion Reports Second Quarter 2025 Financial Results and Corporate Highlights

SAN CARLOS, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today reported its financial results for the second quarter ended June 30, 2025, and provided a business update.

Biomea Fusion Reports Second Quarter 2025 Financial Results and Corporate Highlights

Biomea Fusion Appoints Julianne Averill to its Board of Directors

SAN CARLOS, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced the appointment of Julianne Averill to its Board of Directors (the “Board”), effective July 22, 2025.

Biomea Fusion Appoints Julianne Averill to its Board of Directors

Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)

SAN CARLOS, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Biomea or Biomea Fusion) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced the presentation of new preclinical and clinical data for icovamenib, the company's investigational oral menin inhibitor, at the 85th Scientific Sessions of the American Diabetes Association (ADA) June 20–23, 2025 in Chicago.

Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)

Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates

Dose-dependent, marked reductions in food intake and significant weight loss observed in obese cynomolgus monkeys BMF-650 compared favorably to published data of a leading GLP-1 RA candidate IND filing on track for the second half of 2025; with Phase I study initiation in obese, otherwise healthy volunteers anticipated late 2025 REDWOOD CITY, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced new preclinical findings from a 28-day weight loss study in obese non-human primates evaluating BMF-650, the Company's investigational, next-generation oral small molecule glucagon-like peptide-1 receptor agonist (GLP-1 RA).

Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates

Biomea Fusion Shares Fall After Pricing Underwritten Public Offering

Shares of Biomea Fusion sank after the company disclosed the pricing of its previously announced underwritten public offering.

Biomea Fusion Shares Fall After Pricing Underwritten Public Offering

Biomea Fusion Announces Pricing of Public Offering of Securities

REDWOOD CITY, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced the pricing of its previously announced underwritten public offering consisting of (i) 19,450,000 shares of its common stock and accompanying warrants to purchase an aggregate of 19,450,000 shares of common stock (or pre-funded warrants in lieu thereof) and (ii) in lieu of common stock, to certain investors, pre-funded warrants to purchase an aggregate of up to 550,000 shares of its common stock and accompanying warrants to purchase an aggregate of 550,000 shares of common stock (or pre-funded warrants in lieu thereof), at an exercise price of $0.0001 per pre-funded warrant.

Biomea Fusion Announces Pricing of Public Offering of Securities

Stocks to Watch: Biomea Fusion, Bitdeer Technologies

Biomea Fusion commenced an underwritten public offering of shares. The stock sank 27% to $2.13 in postmarket trading Tuesday.

Stocks to Watch: Biomea Fusion, Bitdeer Technologies

Biomea Fusion Announces Proposed Public Offering of Securities

REDWOOD CITY, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, announced today that it has commenced an underwritten public offering of shares of its common stock and accompanying warrants to purchase shares of its common stock (or pre-funded warrants in lieu thereof) and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock and accompanying warrants to purchase shares of its common stock (or pre-funded warrants in lieu thereof).

Biomea Fusion Announces Proposed Public Offering of Securities

Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025

New clinical results show sustained CRi, deep bone marrow responses, and encouraging survival in FLT3-mutant AML patients, including those previously treated with gilteritinib New clinical results show sustained CRi, deep bone marrow responses, and encouraging survival in FLT3-mutant AML patients, including those previously treated with gilteritinib

$Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025$

See News Rankings

Charts implemented using Lightweight Charts™